Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:10:23 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



News for U:LNTH from 2023-05-18 to 2024-05-17 - 27 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-15 16:30U:LNTHNews ReleaseLantheus Announces Executive Appointments to Accelerate Innovation
2024-05-02 07:00U:LNTHNews ReleaseLantheus Reports First Quarter 2024 Financial Results
2024-04-18 08:00U:LNTHNews ReleaseLantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
2024-03-05 08:30U:LNTHNews ReleaseLantheus to Present at the Leerink Partners Global Biopharma Conference 2024
2024-03-04 08:30U:LNTHNews ReleaseLantheus Announces the FDA Approval of DEFINITY(TM) (Perflutren Lipid Microsphere) for Pediatric Patients
2024-02-28 08:30U:LNTHNews ReleaseLantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
2024-02-26 08:30U:LNTHNews ReleaseLantheus to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-22 07:00U:LNTHNews ReleaseLantheus Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 08:30U:LNTHNews ReleaseLantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
2024-02-08 08:00U:LNTHNews ReleaseLantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
2024-01-23 07:45U:LNTHNews ReleaseLantheus Announces CEO Succession Plan
2024-01-11 08:00U:LNTHNews ReleaseLantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA ‚ ® (Lutetium Lu 177 Dotatate)
2024-01-09 08:00U:LNTHNews ReleaseLantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
2024-01-09 07:55U:LNTHNews ReleaseLantheus Reports Preliminary Fiscal Year 2023 Revenue
2024-01-03 08:30U:LNTHNews ReleaseLantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 07:30U:LNTHNews ReleaseLantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
2023-11-08 08:00U:LNTHNews ReleaseLantheus to Present at the Jefferies London Healthcare Conference
2023-11-02 07:00U:LNTHNews ReleaseLantheus Reports Third Quarter 2023 Financial Results
2023-10-19 08:00U:LNTHNews ReleaseLantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on ‚  November 2, 2023, at 8:00 a.m. Eastern Time
2023-09-01 08:30U:LNTHNews ReleaseLantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI ¢ „ ¢ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
2023-08-31 08:00U:LNTHNews ReleaseLantheus to Present at the Wells Fargo Healthcare Conference
2023-08-03 07:10U:LNTHNews ReleaseLantheus Announces Agreement to Sell RELISTOR ‚ ® Royalties to HealthCare Royalty
2023-08-03 07:00U:LNTHNews ReleaseLantheus Reports Second Quarter 2023 Financial Results
2023-07-20 08:30U:LNTHNews ReleaseLantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
2023-06-12 08:30U:LNTHNews ReleaseLantheus Announces Presentations Featuring PYLARIFY AI ¢ „ ¢ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
2023-06-01 08:30U:LNTHNews ReleaseLantheus to Present at the Jefferies Healthcare Conference
2023-05-23 08:30U:LNTHNews ReleaseLantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR